Treatment-refractory schizophrenia

Asaf Caspi, Michael Davidson, Carol A. Tamminga

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Between one-third and one-half of the individuals who meet diagnostic criteria for schizophrenia remain actively ill despite optimal pharmacological treatment. These individuals tend to progressively deteriorate in terms of social and vocational functioning despite major public and private investments in their rehabilitation. For patients who do not respond to the first prescribed antipsychotic drug, current clinical practice is to switch to a second and a third drug, and eventually to dozapine, the only antipsychotic drug proven to be effective in treatment-refractory schizophrenia (TRS). Occasionally, two antipsychotics are given concomitantly or psychotropic drugs are added to antipsychotic drugs; however, very few empirical data exist to support this practice. Although there are many exceptions, patients who do not benefit from the first prescribed drug will not benefit from any pharmacological intervention. Therefore, efforts are under way to determine the reason for lack of response to available treatments and devise novel, more effective treatments. To be successful these efforts must result in a more specific definition of TRS, as well as in a better understanding of the illness pathophysiology and the mechanism of action of the drugs.

Original languageEnglish (US)
Pages (from-to)61-70
Number of pages10
JournalDialogues in Clinical Neuroscience
Volume6
Issue number1
StatePublished - 2004

Fingerprint

Schizophrenia
Antipsychotic Agents
Pharmaceutical Preparations
Pharmacology
Therapeutics
Psychotropic Drugs
Rehabilitation

Keywords

  • Antipsychotic agent
  • Mechanism for treatment-refractory schizophrenia
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Treatment-refractory schizophrenia. / Caspi, Asaf; Davidson, Michael; Tamminga, Carol A.

In: Dialogues in Clinical Neuroscience, Vol. 6, No. 1, 2004, p. 61-70.

Research output: Contribution to journalArticle

Caspi, A, Davidson, M & Tamminga, CA 2004, 'Treatment-refractory schizophrenia', Dialogues in Clinical Neuroscience, vol. 6, no. 1, pp. 61-70.
Caspi, Asaf ; Davidson, Michael ; Tamminga, Carol A. / Treatment-refractory schizophrenia. In: Dialogues in Clinical Neuroscience. 2004 ; Vol. 6, No. 1. pp. 61-70.
@article{93f44cd990b94648b9987efdcb8186a1,
title = "Treatment-refractory schizophrenia",
abstract = "Between one-third and one-half of the individuals who meet diagnostic criteria for schizophrenia remain actively ill despite optimal pharmacological treatment. These individuals tend to progressively deteriorate in terms of social and vocational functioning despite major public and private investments in their rehabilitation. For patients who do not respond to the first prescribed antipsychotic drug, current clinical practice is to switch to a second and a third drug, and eventually to dozapine, the only antipsychotic drug proven to be effective in treatment-refractory schizophrenia (TRS). Occasionally, two antipsychotics are given concomitantly or psychotropic drugs are added to antipsychotic drugs; however, very few empirical data exist to support this practice. Although there are many exceptions, patients who do not benefit from the first prescribed drug will not benefit from any pharmacological intervention. Therefore, efforts are under way to determine the reason for lack of response to available treatments and devise novel, more effective treatments. To be successful these efforts must result in a more specific definition of TRS, as well as in a better understanding of the illness pathophysiology and the mechanism of action of the drugs.",
keywords = "Antipsychotic agent, Mechanism for treatment-refractory schizophrenia, Schizophrenia, Treatment",
author = "Asaf Caspi and Michael Davidson and Tamminga, {Carol A.}",
year = "2004",
language = "English (US)",
volume = "6",
pages = "61--70",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "1",

}

TY - JOUR

T1 - Treatment-refractory schizophrenia

AU - Caspi, Asaf

AU - Davidson, Michael

AU - Tamminga, Carol A.

PY - 2004

Y1 - 2004

N2 - Between one-third and one-half of the individuals who meet diagnostic criteria for schizophrenia remain actively ill despite optimal pharmacological treatment. These individuals tend to progressively deteriorate in terms of social and vocational functioning despite major public and private investments in their rehabilitation. For patients who do not respond to the first prescribed antipsychotic drug, current clinical practice is to switch to a second and a third drug, and eventually to dozapine, the only antipsychotic drug proven to be effective in treatment-refractory schizophrenia (TRS). Occasionally, two antipsychotics are given concomitantly or psychotropic drugs are added to antipsychotic drugs; however, very few empirical data exist to support this practice. Although there are many exceptions, patients who do not benefit from the first prescribed drug will not benefit from any pharmacological intervention. Therefore, efforts are under way to determine the reason for lack of response to available treatments and devise novel, more effective treatments. To be successful these efforts must result in a more specific definition of TRS, as well as in a better understanding of the illness pathophysiology and the mechanism of action of the drugs.

AB - Between one-third and one-half of the individuals who meet diagnostic criteria for schizophrenia remain actively ill despite optimal pharmacological treatment. These individuals tend to progressively deteriorate in terms of social and vocational functioning despite major public and private investments in their rehabilitation. For patients who do not respond to the first prescribed antipsychotic drug, current clinical practice is to switch to a second and a third drug, and eventually to dozapine, the only antipsychotic drug proven to be effective in treatment-refractory schizophrenia (TRS). Occasionally, two antipsychotics are given concomitantly or psychotropic drugs are added to antipsychotic drugs; however, very few empirical data exist to support this practice. Although there are many exceptions, patients who do not benefit from the first prescribed drug will not benefit from any pharmacological intervention. Therefore, efforts are under way to determine the reason for lack of response to available treatments and devise novel, more effective treatments. To be successful these efforts must result in a more specific definition of TRS, as well as in a better understanding of the illness pathophysiology and the mechanism of action of the drugs.

KW - Antipsychotic agent

KW - Mechanism for treatment-refractory schizophrenia

KW - Schizophrenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=1842615118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842615118&partnerID=8YFLogxK

M3 - Article

C2 - 22034144

AN - SCOPUS:1842615118

VL - 6

SP - 61

EP - 70

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 1

ER -